United States Patent 11,053,502 (LDHA dsRNA): Scope, Claim Breadth, and US Patent Landscape
United States Patent 11,053,502 claims chemically modified dsRNA (sense/antisense) that inhibits lactic acid dehydrogenase A (LDHA) expression. The core claim family is centered on an antisense sequence anchored to SEQ ID NO: 7193 (5′-UCAGAUAAAAAGGACAACAUGC-3′), with layered breadth controls on (i) sequence identity tolerance, (ii) antisense length, (iii) chemical modification (2′-O-methyl, 2′-fluoro), (iv) backbone chemistry (methylphosphonate, phosphorothioate, phosphotriester), and (v) delivery/targeting via GalNAc conjugation. The dependent claims also narrow to a specific functional potency threshold and defined structural elements (3′ overhang; fully complementary pairing; tetraloop-containing sense strand).
What is the invention scope defined by the independent claim?
Claim 1: What is actually covered?
Claim 1 defines a dsRNA agent for inhibiting LDHA expression with the following structural and functional requirements:
A. Modality
- Double stranded ribonucleic acid (dsRNA) comprising:
- sense strand
- antisense strand
- forming a double stranded region
B. Targeting sequence (antisense anchor)
- Antisense strand comprises at least 19 consecutive nucleotides that are:
- differing by 3 or fewer nucleotides from the nucleotide sequence:
- 5′-UCAGAUAAAAAGGACAACAUGC-3′ (SEQ ID NO: 7193)
C. Antisense length
- Antisense strand length is 19 to 35 nucleotides
D. Functional endpoint (not in claim 1; appears in dependent claim 16)
- Claim 1 does not explicitly require potency, but the family later narrows with a measurable reduction threshold.
Net read across Claim 1: The “infringement trigger” is an LDHA-suppressive dsRNA whose antisense contains a core subsequence at high similarity to SEQ ID NO: 7193, under a defined length window.
Claim 18: How the scope tightens in the main second independent claim
Claim 18 is another independent claim that adds three major chemical and delivery constraints over the Claim 1 concept:
- Antisense: same anchor (>= 19 consecutive nucleotides; <=3 mismatches)
- Antisense length: 19 to 35
- All nucleotides of the double-stranded region are modified
- modified nucleotides are from:
- 2′-O-methyl-modified and/or 2′-fluoro-modified nucleotides
- dsRNA is attached to one or more GalNAc moieties
Net read: Claim 18 is a “GalNAc + fully modified duplex” version of the Claim 1 concept. If a candidate product matches this profile, it is structurally inside the more commercially relevant chemical/delivery format.
Claim 24: How broadening occurs via a different mismatch framing
Claim 24 shifts breadth via a different pairing of:
- at least 15 consecutive nucleotides
- differing by 4 or fewer nucleotides from SEQ ID NO: 7193
- antisense length: 19 to 35
This is a materially different identity test:
- Claim 1 requires >=19 consecutive with <=3 mismatches
- Claim 24 allows >=15 consecutive with <=4 mismatches
Net read: Claim 24 can capture designs with fewer contiguous identity bases while still maintaining substantial similarity to the LDHA-targeting region.
Claim-by-claim scope map: what is broad vs what is narrow?
Sequence identity and length controls
Core identity anchor: SEQ ID NO: 7193
- Claim 1: >=19 consecutive nucleotides, <=3 differences
- Claim 2: <=2 differences
- Claim 3: <=1 difference
- Claim 4: >=19 consecutive nucleotides (no mismatch limit stated in the text you provided, but the later structure implies it is still tied to “from” that sequence)
- Claim 24: >=15 consecutive nucleotides, <=4 differences
Antisense length
- Claim 1: 19 to 35
- Claim 12: 19 to 23
- Claim 13: 22
- Claim 19/21: further narrowed in the GalNAc and phosphorothioate-dependent cluster
Key potency anchor (functional limitation)
- Claim 16: reduces LDHA mRNA levels by at least 70% in a cell at >=1 nM
Chemical modification breadth
Fully modified duplex
- Claim 5: all nucleotides of the double-stranded region are modified
- Claim 6: modifications are 2′-O-methyl and 2′-fluoro
- Claim 7: all nucleotides of both sense and antisense are modified (stronger than claim 5)
- Claim 18: explicitly includes the Claim 5 + Claim 6 requirements
Backbone / linkage breadth
- Claim 9: phosphate backbone modification is selected from:
- methylphosphonate
- phosphorothioate
- phosphotriester
- Claim 10: phosphorothioate linkage
- Claim 11: both sense and antisense comprise phosphorothioate linkage
- Claim 20: sense and antisense comprise phosphorothioate linkage
Delivery/targeting constraint
- Claim 8: dsRNA is attached to one or more GalNAc moieties
- Claim 18: includes GalNAc in the independent scope, making it the most “product-likely” claim posture in this set
Structural pairing and end-effects
- Claim 14: sense and antisense are fully complementary
- Claim 15: dsRNA has a 3′ overhang of 2 nucleotides
- Claim 22: sense strand is between 32 and 80 nucleotides and comprises a tetraloop
Cellular and composition claims (downstream coverage)
- Claim 17: pharmaceutical composition (dsRNA + carrier)
- Claim 23: another pharmaceutical composition tied to claim 20
- Claim 28-30: mammalian cells comprising the dsRNA (Claim 1 / 20 / 25 variants)
Numerical claim boundary table (practical infringement “design space”)
| Dimension |
Claim 1 |
Claim 18 |
Claim 24 |
Key narrowing claims |
| Antisense anchor subsequence |
>=19 consecutive from SEQ ID 7193 |
>=19 consecutive from SEQ ID 7193 |
>=15 consecutive from SEQ ID 7193 |
Claims 2-3 tighten mismatch count; Claim 19/21 further tie length and linkage |
| Allowed mismatches vs SEQ ID 7193 |
<=3 differences |
<=3 differences |
<=4 differences |
Claim 2: <=2; Claim 3: <=1 |
| Antisense length |
19-35 nt |
19-35 nt |
19-35 nt |
Claim 12: 19-23; Claim 13: 22; Claim 21: 22 |
| Double-stranded region modifications |
Not required in claim 1 |
Required: all nucleotides modified |
Required: all nucleotides modified |
Claim 6 selects 2′-O-methyl and 2′-fluoro |
| Allowed base modifications |
Not required in claim 1 |
2′-O-methyl and/or 2′-fluoro |
2′-O-methyl and/or 2′-fluoro |
Claim 7 makes all nucleotides (sense+antisense) modified |
| Backbone chemistry |
Not required in claim 1 |
Not required in claim 18 |
Not required in claim 24 |
Claims 9-11 and 20-21 introduce methylphosphonate / phosphorothioate / phosphotriester and phosphorothioate linkage |
| GalNAc conjugate |
Not required in claim 1 |
Required |
Required in claim 25 (dependent) |
Claim 8 in claim 1 path; claim 18 includes GalNAc directly |
| Potency |
Not required in claim 1 |
Not required in claim 18 |
Not required in claim 24 |
Claim 16: >=70% LDHA mRNA knockdown at >=1 nM |
| Duplex pairing |
Not required in claim 1 |
Not required in claim 18 |
Not required in claim 24 |
Claim 14: fully complementary |
| End structure |
Not required in claim 1 |
Not required in claim 18 |
Not required in claim 24 |
Claim 15: 3′ overhang of 2 |
| Sense length / tetraloop |
Not required in claim 1 |
Not required in claim 18 |
Not required in claim 24 |
Claim 22: sense 32-80 nt with tetraloop |
Patent landscape: where this claim likely sits relative to the dsRNA + LDHA field
Positioning within the dsRNA chemical-delivery IP landscape
This patent’s claim structure tracks three dominant dsRNA protection themes that recur across the RNAi landscape:
-
Sequence-defined RNA target engagement
- Anchored antisense sequences (here SEQ ID NO: 7193) with explicit mismatch tolerances.
- This is the primary patentability axis for RNAi therapeutics once the broader “dsRNA for gene silencing” concept becomes crowded.
-
Chemical stabilization and nuclease resistance
- Claims cover fully modified duplexes using 2′-O-methyl and 2′-fluoro, plus broad backbone chemistry including phosphorothioate.
- This aligns with the common move away from unmodified dsRNA due to stability and safety constraints.
-
Targeted delivery
- GalNAc conjugation is claimed as a core structural element (Claim 8; required in Claim 18).
- This is a commercially meaningful pathway for liver-targeted RNAi agents.
LDHA as the functional target
LDHA is frequently addressed by oncology programs aiming to disrupt tumor metabolism. A dsRNA platform patent that names LDHA explicitly narrows the landscape to:
- patents that already claim LDHA inhibition using RNAi
- or patents that broadly claim RNAi agents targeting metabolic genes and later descendants that incorporate LDHA-specific sequences
In practice, sequence-anchored claims like these tend to create a “wafer” effect across the product set: even when the chemical backbone and delivery are similar to competitors, a competitor must avoid the claimed antisense design region (or avoid the combination of required chemical/delivery elements present in the independent claims).
Litigation and freedom-to-operate risk signals embedded in these claims
Independent claims include multiple “product-like” constraints
- Claim 18 includes the combination of:
- SEQ ID 7193-based antisense identity tolerance
- full ds-region chemical modification (2′-O-methyl and/or 2′-fluoro)
- GalNAc conjugation
- This combination is harder for a design-around because many commercially deployed dsRNA formats use exactly these stabilizers and targeting moieties.
Secondary independent claim broadens identity via contiguous subsequence + mismatch
- Claim 24 can capture antisense designs that reduce identity length (>=15) while increasing mismatch allowance (<=4).
- This matters for design-around strategies that might keep a “close” seed region but alter the rest.
Functional claim narrows the “capability” rather than only the sequence
- Claim 16 ties infringement to a measurable biology endpoint:
- “reduces LDHA mRNA levels by at least 70% in a cell at >=1 nM.”
- That can matter in disputes where defendants argue that their sequence is different but still achieves LDHA knockdown.
Practical scope takeaway: the critical infringement test
A product will be within the patent’s high-value coverage if it matches, at minimum, one of the following claim clusters:
-
Claim 1 path (sequence + length):
- dsRNA with antisense containing a subsequence matching SEQ ID NO: 7193 with >=19 consecutive and <=3 mismatches
- antisense length 19-35
- LDHA expression inhibition
-
Claim 18 path (sequence + chemical + delivery):
- the above sequence requirements
- all ds-region nucleotides modified with 2′-O-methyl and/or 2′-fluoro
- GalNAc conjugation
-
Claim 24 path (alternate identity window):
- antisense containing >=15 consecutive with <=4 differences to SEQ ID 7193
- antisense length 19-35
Then, avoid additional narrow claim features if trying to reduce overlap:
- phosphorothioate linkage and full complementarity
- 3′ overhang of 2 nucleotides
- potency threshold (>=70% LDHA mRNA reduction at >=1 nM)
- tetraloop-containing sense length range (32-80)
Key Takeaways
- The patent’s center of gravity is an antisense anchor around SEQ ID NO: 7193 with explicit mismatch and contiguous subsequence rules. The broadest independent claims are Claim 1 (sequence-defined) and Claim 18 (sequence plus full chemical modification plus GalNAc).
- Claim 24 expands the identity window by lowering contiguous identity length to >=15 nucleotides while allowing up to 4 differences, increasing the chance of capturing “variant” antisense designs that maintain a partial match.
- Commercially relevant formats are directly claimed: fully 2′-modified duplexes and GalNAc targeting appear in an independent claim (Claim 18), which raises design-around difficulty for product-like molecules.
- A functional endpoint is embedded in dependent Claim 16 (>=70% LDHA mRNA knockdown at >=1 nM), adding a biology-based infringement hook.
FAQs
1) Which claim is most likely to be product-relevant for a GalNAc dsRNA LDHA agent?
Claim 18, because it is independent and explicitly requires GalNAc attachment plus all double-stranded region nucleotides modified with 2′-O-methyl and/or 2′-fluoro.
2) What antisense sequence feature is the core design “must avoid” element?
The antisense must contain at least 19 consecutive nucleotides that differ by 3 or fewer from SEQ ID NO: 7193 (Claim 1), or at least 15 consecutive that differ by 4 or fewer (Claim 24).
3) Does the patent require a specific backbone chemistry in the broadest independent claim?
No. Backbone modifications are introduced in dependent claims (e.g., methylphosphonate/phosphorothioate/phosphotriester in Claim 9; phosphorothioate linkage in Claims 10-11 and 20-21). Claim 1 itself does not mandate a specific linkage type.
4) What chemical modifications are required in the independent GalNAc claim?
Claim 18 requires all nucleotides of the double-stranded region be modified, selected from 2′-O-methyl and 2′-fluoro.
5) Can a competitor avoid the patent by only changing the sense strand length or loop architecture?
Not by sense changes alone if the antisense still satisfies the subsequence identity and length limits tied to SEQ ID NO: 7193. Sense architecture narrowing (tetraloop; 32-80 nt) appears in dependent Claim 22, which affects some variants but does not control the independent sequence anchor.
References
[1] US Patent 11,053,502. “Double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of lactic acid dehydrogenase A (LDHA).” United States Patent and Trademark Office.
